NASDAQ:JUNS Jupiter Neurosciences (JUNS) Stock Price, News & Analysis → The Gold Grab of the Century (From Colonial Metals) (Ad) Free JUNS Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Jupiter Neurosciences alerts: Email Address Ad InvestorPlaceElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. About Jupiter Neurosciences Stock (NASDAQ:JUNS)Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.Read More Ad InvestorPlaceElon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. JUNS Stock News HeadlinesDecember 21, 2023 | usatoday.comFact check: False claim 'Star of Bethlehem' will shine for first time since 1226 on Dec. 21October 8, 2023 | forbes.comWhy We Lie, And The Neuroscience Behind ItMay 4, 2024 | Weiss Ratings (Ad)The #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-up before it’s too late. It’s urgent because it’s what we consider “The #1 Crypto for the AI World.”July 29, 2023 | msn.comHow do you attack brain cancer? A world-class lab in Jupiter is trying something innovative.April 23, 2023 | forbes.comNeuroscience Explains Why You Need To Write Down Your Goals If You Actually Want To Achieve ThemMarch 1, 2023 | morningstar.comJupiter Neurosciences, Inc. Announces Research Breakthrough with JOTROL™ in Parkinson's DiseaseFebruary 23, 2023 | cnet.comWatch Venus and Jupiter Close In on a Glorious ConjunctionJanuary 22, 2023 | finance.yahoo.comFAU STILES-NICHOLSON BRAIN INSTITUTE OPENS HERALDING A NEW ERA IN NEUROSCIENCE AND EDUCATIONMay 4, 2024 | Weiss Ratings (Ad)The #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-up before it’s too late. It’s urgent because it’s what we consider “The #1 Crypto for the AI World.”January 22, 2023 | bizjournals.comFAU opens $45M neuroscience building (Photos)December 5, 2022 | seekingalpha.comResveratrol drug developer Jupiter Neuroscience sets price for proposed $15M IPOSeptember 25, 2022 | investing.comJupiter Neurosciences Inc (JUNS)September 21, 2022 | nasdaq.comDaily Markets: Markets Wait for Fed's Rate Decision and Powell's SpeechSeptember 19, 2022 | seekingalpha.comStocks To Watch: Investors Eye Fed Meeting, Nvidia's Tech Event And Porsche IPOSeptember 14, 2022 | nasdaq.comDaily Markets: No Short Path to Bringing Inflation Down to 2% TargetSeptember 13, 2022 | msn.comJupiter Neurosciences, Inc IPOs Tomorrow, Here's What You Need To KnowSeptember 13, 2022 | nasdaq.comDaily Markets: Inflation Report Sure to Move Markets, But Not FedSeptember 12, 2022 | nasdaq.comDaily Markets: Waiting for Inflation Data, the Dollar Trades OffSeptember 6, 2022 | benzinga.comJupiter Neurosciences, Inc To Start Trading TomorrowSee More Headlines Receive JUNS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jupiter Neurosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:JUNS CUSIPN/A CIK1679628 Webwww.jupiterorphan.com Phone561 406 6154FaxN/AEmployees5Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Christer Rosen (Age 69)Co-Founder, CEO & Chairman Comp: $632.23kMs. Alison D. Silva MA (Age 43)MS, Pres, Chief Bus. Officer & Director Dr. Claes Wahlestedt M.D. (Age 63)Ph.D., Co-Founder, Co-Chairman of Scientific Advisory Board & Consulting Chief Medical Officer Dr. Marshall Hayward Ph.D. (Age 67)Co-Founder, Chief Scientific Officer & Director Comp: $441.75kMs. Dana Eschenburg Perez CPA (Age 45)CFO, Sec. & Treasurer Comp: $360.87kDr. Shaun P. Brothers Ph.D. (Age 43)Co-Founder, Consulting Head of Scientific Research & Member of Scientific Advisory Board Mr. Alexander Rosen (Age 31)Co-Founder & Chief Admin. Officer More ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW60 Degrees PharmaceuticalsNASDAQ:SXTPWAlpha Tau MedicalNASDAQ:DRTSWApollomicsNASDAQ:APLMWArtelo BiosciencesNASDAQ:ARTLWView All Competitors JUNS Stock Analysis - Frequently Asked Questions When did Jupiter Neurosciences IPO? Jupiter Neurosciences (JUNS) raised $15 million in an initial public offering (IPO) on Wednesday, September 21st 2022. The company issued 2,500,000 shares at a price of $5.00-$7.00 per share. Spartan Capital acted as the underwriter for the IPO. This page (NASDAQ:JUNS) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchCould Your Accounts Be Frozen?Allegiance GoldThe Gold Grab of the CenturyColonial MetalsStock-Picking AI Predicts #1 Stock of 2024AltimetryThe A.I. story nobody is telling you (Read ASAP)TradeSmithHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jupiter Neurosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
